Commercial AgreementsLUCD has signed its first agreement to pay for EsoGuard under state biomarker legislation with Blue Cross Blue Shield of Rhode Island.
Price Target IncreaseAnalysts are increasing top-line estimates, generating higher cash flows in the DCF model, and thereby raising the 12-month price target to $5.00 from $4.00.
Regulatory MilestoneThe company has reached a milestone in its regulatory pathway by submitting its clinical data package for Medicare coverage, which is expected to significantly increase adoption.